FilingSEC EDGAR8-K
Apyx Medical Reports $14.0 Million Revenue and $1.8 Million Net Loss for Q3 2026
· SEC accepted
StageCommercial Stage
Filing content
The company reported a 9% increase in revenue to $14.0 million driven by Surgical Aesthetics growth, with a narrowed net loss of $1.8 million for the third quarter of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…